Moolec Science’s General Counsel Buys 1,909 Shares, Signals Long‑Term Confidence Amid Volatile Market Fluctuations

Insider Holdings Spotlight: Moolec Science’s General Counsel Holds 1,909 Shares Montaron Estrada Gloria, the company’s General Counsel, has filed a holding transaction under form 3, reporting ownership of 1,909 ordinary shares. The filing, dated March 18 2026, reflects a modest stake in a company whose shares have been volatile, trading near $10.01 after a steep 91 % decline over the past year. While the holding itself is small relative to the company’s market cap of roughly $7.3 million, it signals that legal leadership remains invested in Moolec’s long‑term trajectory.

What This Means for Investors For investors, a holding by a senior officer can be a subtle endorsement of management’s strategic direction. With the company’s stock oscillating between a 52‑week low of $3.08 and a high of $157.05, the General Counsel’s stake suggests confidence in the molecular‑farming platform, despite recent market skepticism. The filing’s lack of a transaction price (0.00 $) and a neutral sentiment score imply that no active buying or selling occurred, reinforcing the view that the officer is not reacting to short‑term price swings but rather supporting a long‑term play.

Insider Activity Across the Board Moolec’s insider landscape is comparatively quiet, with the CEO and CTO each executing three transactions in the most recent filing cycle, and the General Counsel the sole officer with a single holding. This concentration of activity among top executives indicates that the leadership team is aligning their interests closely with shareholders, a positive signal for governance. However, the limited volume of trades also suggests a cautious approach, potentially reflecting uncertainty in a rapidly evolving alternative‑protein market.

Profile of Montaron Estrada Gloria Estrada Gloria’s public transaction history is sparse—only one holding entry appears in the SEC database, with no prior purchases or sales. The absence of a trading record points to a conservative strategy: maintaining a baseline stake without engaging in speculative trades. Her role as General Counsel, combined with this disciplined approach, positions her as a stabilizing force. Investors can view her holdings as an indicator that the company’s legal leadership is committed to navigating regulatory and commercial challenges without seeking short‑term gains.

Looking Ahead Moolec Science’s future will hinge on scaling its molecular‑farming technology and penetrating new markets. The modest yet steady insider holdings suggest that senior management remains invested in the company’s potential, even amid a bearish market trend. For shareholders, the General Counsel’s holding—paired with the broader leadership’s restrained trading—could signal a long‑term belief in Moolec’s value proposition. Monitoring future filings for any shifts in ownership will be key, as changes could foreshadow strategic pivots or confidence swings in the company’s ambitious protein platform.